Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 0.97B P/E - EPS this Y -172.00% Ern Qtrly Grth -
Income -70.74M Forward P/E -5.47 EPS next Y -29.40% 50D Avg Chg -18.00%
Sales 127.66M PEG - EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book 12.62 EPS next 5Y - 52W High Chg -56.00%
Recommedations 2.10 Quick Ratio 2.30 Shares Outstanding 202.62M 52W Low Chg 2.00%
Insider Own 0.43% ROA -12.40% Shares Float 168.40M Beta 1.21
Inst Own 88.40% ROE -413.68% Shares Shorted/Prior 10.43M/17.42M Price 4.81
Gross Margin -11.02% Profit Margin -55.41% Avg. Volume 1,561,895 Target Price 9.64
Oper. Margin -42.33% Earnings Date Feb 10 Volume 1,241,863 Change -2.24%
ImmunoGen, Inc. News
11/24/21 ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/17/21 ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
11/16/21 ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
11/11/21 Implied Volatility Surging for ImmunoGen (IMGN) Stock Options
11/04/21 ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
11/01/21 ImmunoGen (IMGN) Q3 Loss Narrower Than Expected, Revenues Lag
11/01/21 ImmunoGen's (NASDAQ:IMGN) investors will be pleased with their solid 272% return over the last five years
10/29/21 ImmunoGen, inc (IMGN) Q3 2021 Earnings Call Transcript
10/29/21 ImmunoGen (IMGN) Reports Q3 Loss, Misses Revenue Estimates
10/29/21 ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
10/22/21 Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for
10/19/21 Hedge Funds Are Crazy About ImmunoGen, Inc. (IMGN)
10/14/21 ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
09/22/21 ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
08/02/21 ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag
07/30/21 ImmunoGen, inc (IMGN) Q2 2021 Earnings Call Transcript
07/30/21 ImmunoGen (IMGN) Reports Q2 Loss, Misses Revenue Estimates
07/30/21 ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
07/15/21 ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

IMGN Chatroom

User Image Stonkmoon Posted - 2 days ago

$IMGN 2021-11-24 16:30 ET ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://stonkmoon.com/news/IMGN/8d9036c257cd297bd5135ce79ac6ebc1

User Image otcdynamics Posted - 2 days ago

$IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.otcdynamics.com/imgn-immunogen-announces-inducement-grants-under-nasdaq-listing-rule-5635c4

User Image STCKPRO Posted - 2 days ago

$IMGN NEW ARTICLE : ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stck.pro/news/IMGN/18620237

User Image fla Posted - 2 days ago

$IMGN [15s. delayed]: Issued Press Release on November 24, 16:30:00: ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635( https://s.flashalert.me/UdG4R

User Image cctranscripts Posted - 2 days ago

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://conferencecalltranscripts.com/summary/?id=336355&pr=true $IMGN

User Image Quantisnow Posted - 2 days ago

$IMGN 📰 ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://quantisnow.com/insight/2056375?s=s 45 seconds delayed.

User Image Stock_Titan Posted - 2 days ago

$IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/IMGN/immuno-gen-announces-inducement-grants-under-nasdaq-listing-rule-4hoifhnwnkx6.html

User Image Newsfilter Posted - 2 days ago

$IMGN ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635 https://newsfilter.io/a/0acbb19e9fdadd0fa0630d37d4648368

User Image WebChronicleToday Posted - 2 days ago

$IMGN New Press Release: ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 22, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 327,700 shares of its common stock to ten new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employees’ becoming employees of ImmunoGen in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were n (...) https://webchronicletoday.com?p=194940

User Image Invescent Posted - 3 days ago

$IMGN Data suggest that the overall analyst sentiment for IMGN is bullish. Simplify the way you research stocks with Invescent https://play.google.com/store/apps/details?id=org.invescent.invescent&hl=en_US&gl=US

User Image BMWLTWM3 Posted - 4 days ago

$IMGN ridiculous!

User Image Orlandotrader Posted - 4 days ago

$IMGN All Bio getting Azz Raped this year.

User Image Mattcal44 Posted - 4 days ago

$IMGN

User Image JarvisAlerts Posted - 4 days ago

$IMGN 4P Exp:17-Dec-21 ↓↓ 🔥 Total(Day): $123,700 #UnusualActivity Sign-up free for beta ver.:https://app.jarvisalerts.com charts: courtesy of finviz

User Image SweepCast Posted - 4 days ago

SweepCast alerted: $IMGN with Unusual Options Activity Alerted on $5 CALL Expiring: 12-17-2021 worth 29K🐂 |🥇 Learn How Unusual Options Helps Gain Insights! 🥇

User Image stealin_your_thunder Posted - 4 days ago

$IMGN This context fits IMGN's upcoming readout and why the FDA asked them to run the SOROYA trial in patients with "high" FRα expression, based on the results from the FORWARD 1 trial.

User Image JarvisAlerts Posted - 4 days ago

$IMGN 4P Exp:17-Dec-21 ↓↓ 🔥 Total(Day): $123,700 #UnusualActivity Sign-up free for beta ver.:https://app.jarvisalerts.com charts: courtesy of finviz

User Image Loladus Posted - 5 days ago

$IMGN Guys, Immunogen consolidating well and ready to go to 6,6$! By the way check out Fluidigm. FLDM buyout started by activist fund Caligan Partners (13D) and reported by Reuters and Bloomberg. Negotiations confirmed by Fluidigm itself on November 8. Activist Group Neuberger Berman filed 13D on November 18. Enjoy +500% within November-January!

User Image Tzip Posted - 5 days ago

$IMGN Ahh welcome 4s. This thing is garbage

User Image Tzip Posted - 5 days ago

$IMGN thankfully we only lose dollars 4 days this week due to the holiday

User Image DGANG3 Posted - 6 days ago

$IMGN Well it has been an interesting couple of weeks. The price rises and then promptly gets beaten down. Is it manipulation? Does someone know something that we don't? What was really upsetting was that the folks on Investor Villager started to doubt themselves and wondered if they were at risk of it not coming together over the next 6 months for IMGN. After analyzing all the information available which includes a drug approval during 2022, 3 trials providing different levels of results that can impact the price, new partnerships in the works, and the hiring of a team to go commercial, I believe the following options can be occurring: Everything is falling in place and we shall be rewarded for our patience, the stock is being manipulated or Eunady is buying time with a smokescreen of all the hires because things are shaky for MIRV? We should be trading at $10-12/sh based on the environment of this company today. Positive info will take us to $20 plus.

User Image BioTrader13 Posted - 1 week ago

Upcoming Potential Bio catalysts: $AGLE - Pegzilarginase phase 3 data due 12/2021 $ALDX ADX-102 data due 4Q 2021 $IMGN mirvetuximab - SORAYA phase 3 top-line data due 4Q 2021 with BLA filing expected 1Q 2022 $BBIO AG10 phase 3 top-line part A data due late 2021

User Image tickeron Posted - 1 week ago

A.I.dvisor made a bearish call on $IMGN, netting in a 12.33% gain over 3 weeks https://srnk.us/go/3172381

User Image SweepCastOptions Posted - 1 week ago

SweepCast alerted: $IMGN with Unusual Options Activity Alerted on $6 CALL Expiring: 11-19-2021 worth 26K🐂 |🥇 Start Using SweepCast.com

User Image BMWLTWM3 Posted - 1 week ago

$IMGN options crooks got their $5.00 puts….now beat it so we can break above $7.00 with our news no IMGN 629 and Mirvetuximaub update YE

User Image Marcel_TG Posted - 1 week ago

$IMGN 19.26M short

User Image Hp24 Posted - 1 week ago

$IMGN what news here?

User Image BMWLTWM3 Posted - 1 week ago

$IMGN Market scum have taken 30% off the top in less than 1 month, HATE Wall Street!

User Image Tzip Posted - 1 week ago

$IMGN slow death. 4s ahead with next years cure for cancer the only hope

User Image TreasureGod01 Posted - 1 week ago

$IMGN It's ready to release the horse!

Analyst Ratings
SVB Leerink Market Perform Oct 29, 21
SVB Leerink Market Perform Nov 6, 20
SVB Leerink Market Perform Oct 6, 20
Guggenheim Buy Oct 2, 20
Cowen & Co. Outperform May 6, 19
JP Morgan Underweight Mar 19, 19
Morgan Stanley Equal-Weight Mar 5, 19
H.C. Wainwright Neutral Mar 4, 19
H.C. Wainwright Buy Jan 31, 18
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
FOSTER DAVID G V.P.-Fin., Prin. Acc.. V.P.-Fin., Prin. Acctg. Off. Jan 04 Sell 6.38 11,052 70,512 37,912 01/04/21